why choose us

First received: July 18, 2022

Clinical Trial: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Hepatitis B, Chronic
Fibrosis, Liver
Diabetes Mellitus, Type 2

Study Type: Interventional


Official Title: Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant He

Brief Summary: An exploratory comparison of changes in liver fibrosis through glycemic control within and between groups after administration of Pioglitazone and Evogliptin in chronic hepatitis B patients with type 2 diabetes and liver fibrosis

Read more